Evaluation of Clinical Efficiency of rFVlla in Pediatrics

  • M. Şerban
  • P. Ţepeneu
  • C. Petrescu
  • D. Mihailov
  • C. Jinca
  • W. Schramm
Conference paper

Abstract

One decade ago recombinant activated factor VII (rFVIIa) was introduced as a new therapeutic agent for hemophilia patients with inhibitors (Hedner U, 1988). Very soon, its beneficial effect was also proved in many other diseases (Glanzmann’s thrombasthenia, Bernard Soulier thrombopathia, acquired coagulopathy in renal and hepatic failure, congenital deficiency of factor V, VII, XI, acquired hemophilia etc.) (Schulman S, 1998, Martinowitz, 1999). Its clinical use was based on the recognition of the crucial role of FVIIa in hemostasis, initiated both on extrinsic or intrinsic pathway, even in primary hemostasis. The definition of the indications and the optimal therapeutic regimen for rFVIIa is an ongoing process; the establishment of the doses and administration intervals for a minimum hemostatic level is obviously cumbersome.

Keywords

Obesity Catheter Hepatitis Leukemia Anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hagen FS, Gray CL, O’Hara P. et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA, 1986, 83: 2413Google Scholar
  2. 2.
    Hedner U, Bjoern S, Bernvil L et al. Clinical experience with human plasma derived factor VIIa in patients with hemophilia A and high-titer inhibitors. Haemostasis, 1989, 19: 335PubMedGoogle Scholar
  3. 3.
    Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood, 1989, 73: 359PubMedGoogle Scholar
  4. 4.
    Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coag and Fibrinol, 1990, 1: 307CrossRefGoogle Scholar
  5. 5.
    Hedner U, Ljunberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coag and Fibrinol, 1990, 1: 145Google Scholar
  6. 6.
    Hedner U, Feldstedt S, Glazer S. Recombinant FVIIa in hemophilia treatment. In: Hemophilia and von Willebrand’s Disease in the 1990s, Lusher JM, Kessler CM, eds, Elsevier Science Publishers B.V., 1991Google Scholar
  7. 7.
    Schulman S. A therapeutic alternative for haemophiliacs with inhibitors. Acta Paediatr 1992, 81: 926CrossRefGoogle Scholar
  8. 8.
    Ingerslev J, Knudsen L, Sindet-Petersen S. Hemostatic efficacy of recombinant factor VIIa in haemophilia patients with inhibitors. Abstract presented at the XXth International Congress of the World Federation of Haemophilia, Athens, Greece, 1992, 12–17. 10Google Scholar
  9. 9.
    Kristensen J, Killander A, Hippe E et al. Recombinant factor VIIa (rFVIIa) reduces the bleeding time in patients with thrombocytopenia. Abstract presented at the 35th Annual Meeting of the American Society of Hematology, St. Louis, USA, 1993, 3–7. 12Google Scholar
  10. 10.
    Rappaport S, Nemerson Y, Kisiel W, Lindhal AK, Morrissey J, Wildgoose P, Lyng Hansen L, Nordfang O, Lund-Hansen T, Lusher JM, Ockelford PA, Ingerslev J, Glazer S, Falch JE A report on the ISTH Satellite Symposium: Recombinant Coagulation Factor VIIa: Mechanism of action and clinical experience, New York, 10.07. 1993, p. 1–15Google Scholar
  11. 11.
    Glazer S, Hedner U, Falch JE Clinical update of the use of recombinant factor VIIa. Presented at the International Symposium about Inhibitors and Coagulation Factors, Univ. of North Carolina, Chapell Hill, 1993, 3–5. 11.Google Scholar
  12. 12.
    Ingerslev J. NovoSeven. Clinical Experience and Recommendation, p.1–22, Kontrapunkt A/S, 1995Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • M. Şerban
  • P. Ţepeneu
  • C. Petrescu
  • D. Mihailov
  • C. Jinca
  • W. Schramm

There are no affiliations available

Personalised recommendations